One of the main things I recall from the presentation was that one stage IV cancer patient has completed 15 cycles of kevetrin at 350 mg.....If I am not mistaken a cycle is 28 days, so that means they have been on K for nearly 15 months....must be doing something and it is at suboptimum dosing. Also, 73% of ovarian cancer patients showed P-21 expression and the meeting with FDA on phase II for ovarian is already scheduled.